Definium Therapeutics, Inc. (DFTX)
NasdaqGS · USD · Healthcare · Biotechnology
$35.68 (+0.03%) as of
Key statistics
- Market cap
- 4.79B
- Forward P/E
- -18.39
- EPS (TTM)
- -3.43
- Dividend yield
- 0.00%
- 52-week range
- 10.47 – 49.70
- Beta
- 2.19
- Profit margin
- 0.00%
- Analyst target
- $72.56
- Volume
- 1.05M
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 105
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.